Search Results
Eunice S. Wang, MD, discusses the Quantum First Study
Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important
Eunice S. Wang, MD, discusses the importance hitting the FLT3 target
Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor
Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study
Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent
Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results
Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML
Alexander Perl, MD, discusses the Quantum First Study and potential implications
Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies
Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017
Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML
